A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.
暂无分享,去创建一个
John M Davis | Stefan Leucht | Franziska Schmid | Sandra Schwarz | Caroline Corves | John M. Davis | S. Leucht | C. Rummel-Kluge | C. Asenjo Lobos | K. Komossa | C. Corves | Katja Komossa | Christine Rummel-Kluge | Heike Hunger | Claudia Asenjo Lobos | Franziska Schmid | H. Hunger | S. Schwarz
[1] I. Glick,et al. A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.
[2] R. Rosenheck,et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.
[3] John M. Davis,et al. Dose Response and Dose Equivalence of Antipsychotics , 2004, Journal of clinical psychopharmacology.
[4] G. Simpson,et al. Double-blind study of clozapine dose response in chronic schizophrenia. , 1999, The American journal of psychiatry.
[5] J. Lieberman,et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. , 2006, The American journal of psychiatry.
[6] H. Meltzer,et al. A prospective study of clozapine in treatment-resistant schizophrenic patients , 2004, Psychopharmacology.
[7] G. Remington,et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. , 2001, The American journal of psychiatry.
[8] R. Orwin. A fail-safe N for effect size in meta-analysis. , 1983 .
[9] M. Hummer,et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. , 2005, Archives of general psychiatry.
[10] Alan I Green,et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). , 2003, Archives of general psychiatry.
[11] I. Glick,et al. A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.
[12] J. Newcomer. Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.
[13] J. Lieberman,et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic , 2006 .
[14] J. Lieberman,et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.
[15] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[16] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[17] F. Tarazi,et al. Effects of Newer Antipsychotics on Extrapyramidal Function , 2002, CNS Drugs.
[18] I. Glick,et al. Issues that May Determine the Outcome of Antipsychotic Trials: Industry Sponsorship and Extrapyramidal Side Effect , 2008, Neuropsychopharmacology.
[19] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia , 2005, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[20] N Freemantle,et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.
[21] J. Lieberman,et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. , 2001, The American journal of psychiatry.
[22] J. Lieberman,et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 , 2008, Schizophrenia Research.
[23] Stefan Leucht,et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. , 2006, The American journal of psychiatry.
[24] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[25] J. Olié,et al. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study , 2006, International clinical psychopharmacology.
[26] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[27] M. F. Denisov. Re: Prolactin levels and adverse events in patients treated with risperidone. , 2002, Journal of clinical psychopharmacology.
[28] A. Wieck,et al. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. , 2004, Drugs.
[29] Donald R. Miller,et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. , 2006, American journal of epidemiology.
[30] S. Leucht,et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials , 2009, Molecular Psychiatry.
[31] L. Hranov,et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.
[32] S. Leucht,et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.
[33] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia , 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[34] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[35] R. Murray,et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. , 2006, Health technology assessment.